Systemic Lupus Erythematosus: High Level Of Pipeline Innovation Provides Positive Market Outlook, Says GBI Research
2/18/2014 9:15:37 AM
NEW YORK (GBI Research), 18 February 2014 -- While the Systemic Lupus Erythematosus (SLE) treatment market is predominantly limited to Benlysta and off-label Rituxan, new emerging entrants, which appear to offer significant therapeutic benefits, will cause dramatic changes to the future SLE biological treatment market landscape, says a new report from business intelligence provider GBI Research.
The company’s latest report* states that there are extensive research efforts into innovative biologic programs in the SLE pipeline, which target a wide range of cytokines modulators, as well as including cellular targets of the immune system. In fact, cytokine modulators now constitute the largest proportion (33%) of all active pipeline programs for SLE.
Additionally, several experimental programs exhibit novel properties and mechanisms of action, which are different from those currently available, and are expected to gain marketing approval within the next decade. These include the first-in-class LymphoCide (epratuzumab) and Lupuzor (forigerimod), which have shown positive clinical efficacy and safety profiles on small-scale studies.
Ling Zhuang, Ph.D., Analyst for GBI Research, says: “These first-in-class programs are likely to expand the range of treatments available for SLE patients and establish new niches in the market.”
However, there is a large unmet need both in the diagnosis and treatment of SLE.
Zhuang says: “Due to heterogeneous manifestations, there is no single parameter that is sensitive or specific enough to correctly identify overall or organ-specific disease progression in all SLE patients, thereby hampering disease management and clinical research.
“The main unmet need in the current market is a range of efficient drugs with lower risks of infection, toxicity and minimal impact on fertility, since the overall majority of SLE patients are women of child-bearing age,” Zhuang concludes.
*Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
This report analyzes the market for Systemic Lupus Erythematosus therapeutics and pipeline products, with particular emphasis on first-in-class programs.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at firstname.lastname@example.org.
Help employers find you! Check out all the jobs and post your resume.
comments powered by